EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antidiabetic drug administration prevents bone mineral density loss: Evidence from a two-sample Mendelian randomization study

Mingzhu Chen, Shuisen Lin, Wanqiong Chen, Xiaoqiang Chen iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0300009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Mingzhu Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Quanzhou Medical College, Quanzhou, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Gliclazide, Metformin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Quanzhou City Science and Technology Program, Natural Science Foundation of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to investigate the effect of common antidiabetic drugs on BMD by two-sample Mendelian randomization (MR). The single nucleotide polymorphisms that were strongly associated with insulin, metformin, rosiglitazone and gliclazide were extracted as instrumental variables (IVs) for MR analysis. The inverse variance weighted (IVW) method was used as the primary MR method to assess the causal effect of antidiabetic drugs on BMD, and other MR methods, including Weighted median, MR Egger and Weighted mode, were used for complementary analysis. Reliability and stability were assessed by the leave-one-out test. In the present work, IVW estimation of the causal effect of insulin on heel BMD demonstrated that there was a null effect of insulin on heel BMD (β = 0.765; se = 0.971; P = 0.430), while metformin treatment had a positive effect on heel BMD (β = 1.414; se = 0.460; P = 2.118*10 −3 ). The causal relationship between rosiglitazone and heel BMD analysed by IVW suggested that there was a null effect of rosiglitazone on heel BMD (β = -0.526; se = 1.744; P = 0.763), but the causal effect of gliclazide on heel BMD evaluated by IVW demonstrated that there was a positive effect of gliclazide on heel BMD (β = 2.671; se = 1.340; P = 0.046). In summary, the present work showed that metformin and gliclazide have a role in reducing BMD loss in patients with diabetes and are recommended for BMD loss prevention in diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes MellitusGliclazideMetforminHumansBone DensityGenome-Wide Association StudyHypoglycemic AgentsInsulinInsulin, Regular, HumanMendelian Randomization AnalysisPolymorphism, Single NucleotideReproducibility of ResultsRosiglitazone

Substanzen

GliclazideHypoglycemic AgentsInsulinInsulin, Regular, HumanMetforminRosiglitazone

Autor:innen und Institutionen

  • School of Pharmacy, Quanzhou Medical College, Quanzhou, China.
  • Department of Orthopaedic Surgery, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.

ORCID-Profile: Xiaoqiang Chen

Förderung

  • Quanzhou City Science and Technology Program
  • Natural Science Foundation of Fujian Province

Zitieren

APA

Chen, M., Lin, S., Chen, W., & Chen, X. (2024). Antidiabetic drug administration prevents bone mineral density loss: Evidence from a two-sample Mendelian randomization study. PLOS ONE. https://doi.org/10.1371/journal.pone.0300009

Vancouver

Chen M, Lin S, Chen W, Chen X. Antidiabetic drug administration prevents bone mineral density loss: Evidence from a two-sample Mendelian randomization study. PLOS ONE. 2024. doi:10.1371/journal.pone.0300009

BibTeX
@article{Chen2024,
  author = {Chen, Mingzhu and Lin, Shuisen and Chen, Wanqiong and Chen, Xiaoqiang},
  title = {Antidiabetic drug administration prevents bone mineral density loss: Evidence from a two-sample Mendelian randomization study},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0300009}
}
Kostenlos starten →